Sting data about the safe use of sumatriptan are encouraging. Most of the information from sumatriptan pregnancy registry’s clinical trials and obtained suggest that this drug Mubritinib TAK 165 has no significant influence on organogenesis or spontaneous abortion rate and can be used as a therapeutic alternative s for pregnant women to experience again the onset or worsening of migraine ne-headaches in their first trimester. Readers are cautioned, however, these data on other drugs in this class is not sufficient to draw the same conclusions for all of them. Furthermore, as the majority of data available for sumatriptan exposure during the first quarter alone is involved, or the timing of drug exposure was not reported, caution for use in the neighborhoods weight is ensured And intermediates thereof.
prospective studies of sumatriptan, use s sp ter during pregnancy should be promoted found. Hormonal fluctuations, specifically estrogen Have also been shown to have a great influence on the development of migraine Ne. 5 In the brain affects estrogen as a neuro-modulator, which can affect the density of serotonin receptors, k. As Strogenspiegel sink, since the concentrations of serotonin receptors. Independent ngig of the pathophysiology behind Migr Ne, it is known that each individual a threshold of Migr Ne and has a different level of threshold initiation.6 reaching this threshold is h Frequently the result of a triggering SERS, which also the excess or lack of sleep, the weather / pressure changes, emotional stress, odors, skipping meals, and fluctuating hormone levels, particularly from strogenen.
Once the threshold has been reached, the process of migraine Ne begins.6 8 Migr Ne w During pregnancy because of the st YOUR BIDDING increasing amounts of estrogen, women 50 to 80% experience a decrease in the H Frequency and severity of migraine ne w during pregnancy, especially need during the second and third quarters .5,9 W during the first quarter, however, when concentrations f of estrogen depends on just to rise, then put some women see a increase or new onset of migraines.9 for these women is an appropriate treatment, the basic requirement for the health of the mother of the fetus. A migraine is Ne not in itself a risk for birth defects or miscarriages. However, if the migraine Ne not treated or treated unfairly, k Nnte they lead to discrimination, poor Ern Currency, dehydration, increases htem stress, and can sleep depression.
9 any of these symptoms adversely affect the health of mothers and fetal well being. Nonpharmacologic therapy, such as identification of triggers, biofeedback, massage, yoga and deep breathing have long been the first choice therapy for the treatment of migraine Ne w Taken during pregnancy into account, since they are of little or no risk of mother or fetus.10 If the drug se treatment is required, is often recommended paracetamol in the first place, based on comparisons with other available security updates are available agents.11, 12 Although this drug is more effective if “it is used in combination with aspirin and caffeine administered, it is more effective than placebo when used alone, and safe as monotherapy for the development fetus.13 other options for the acute treatment of certain migraine ne go Ren no stero Meridian Convergence anti-inflammatory compounds, barbiturates, Opio from and alkaloids Ergot, pr sentieren these questions potential when used in pregnancy.3, 14,15